NCT07390617 A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma
| NCT ID | NCT07390617 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Condition | Neuropathy |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2026-01-20 |
| Primary Completion | 2028-01-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2026-01-20 with a primary completion date of 2028-01-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to see how results of nerve tests change in people with urothelial cancer who receive treatment with enfortumab vedotin (EV)
Eligibility Criteria
Inclusion Criteria: * Written informed consent by and HIPAA authorization for release of personal health information obtained from the research participant. * Able to speak and read English to a sufficient level of fluency to provide informed consent and complete the study questionnaires. * Age ≥ 18 years at the time of consent. * ECOG Performance Status of ≤ 3 within 28 days prior to consent. * Histological or cytologically confirmed urothelial carcinoma. * Patients must be planned to start systemic therapy with enfortumab vedotin * At time of enrollment, patients must be planned to start enfortumab with or without pembrolizumab Exclusion Criteria: Subjects meeting any of the criteria below may not participate in the study: * Inability of the subject to understand and comply with study procedures. * Having previously received enfortumab vedotin * Students/employees of the study institution, pregnant women, prisoners, and institutionalized individuals (to prevent enrollment of vulnerable subjects).
Contact & Investigator
Samuel Funt, MD
PRINCIPAL INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Frequently Asked Questions
Who can join the NCT07390617 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Neuropathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07390617 currently recruiting?
Yes, NCT07390617 is actively recruiting participants. Contact the research team at funts@mskcc.org for enrollment information.
Where is the NCT07390617 trial being conducted?
This trial is being conducted at Basking Ridge, United States, Middletown, United States, Montvale, United States, Commack, United States and 3 additional locations.
Who is sponsoring the NCT07390617 clinical trial?
NCT07390617 is sponsored by Memorial Sloan Kettering Cancer Center. The principal investigator is Samuel Funt, MD at Memorial Sloan Kettering Cancer Center. The trial plans to enroll 50 participants.